Respiratory Medicine, Volume 106, Supplement 1, December 2012

A new combination therapy for asthma; bridging the gap between effectiveness in trials and clinical practice?, January 2013, Vol. 106, Supplement 1


A new combination therapy for asthma: bridging the gap between effectiveness in trials and clinical practice?

This overview of the review articles sets out the collection’s aim to provide an insight into the potential for an additional inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) single-inhaler therapy to expand the respiratory physician’s toolbox of treatment approaches, with a view to helping to close the gap between asthma control achieved in randomized controlled trials and that still sought in clinical practice.

Read more

Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma

Prescribing data for Europe show a shift from inhaled corticosteroids (ICSs) prescribed alone or in free combination with long-acting β2-agonists (LABAs) to fixed-dose single-inhaler combinations of these agents. However, existing guidelines provide little advice on selecting a specific ICS/LABA combination therapy for the treatment of asthma.

Read more

Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma

Fluticasone and formoterol have been combined, for the first time, in a single hydrofluoroalkane-based aerosol (flutiform®; fluticasone propionate/formoterol fumarate). Here, we review data from the published randomized, controlled, clinical trials that demonstrate the efficacy and tolerability of this product.

Read more

Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice

This review article summarizes the pharmacological characteristics of the various inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs) available for the treatment of asthma, including the potential for ICS and LABA synergy, and gives an insight into the rationale for the development of the latest ICS/LABA combination approved for asthma maintenance therapy.

Read more


This supplement is sponsored by Mundipharma International Limited and contains papers based on presentations from an advisory meeting of health care professionals held on 22 June 2010, which was also arranged and sponsored by Mundipharma International Limited. Medical writing and editorial support was provided by Oxford PharmaGenesis Limited™ (Oxford, UK). This work was arranged and funded by Mundipharma International Limited (Cambridge, UK).

Please click here for Prescribing information